- Home
- LVO vs CHRS Comparison
LVO vs CHRS Comparison
Compare LVO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVO
- CHRS
- Stock Information
- Founded
- LVO 2009
- CHRS 2010
- Country
- LVO United States
- CHRS United States
- Employees
- LVO N/A
- CHRS N/A
- Industry
- LVO Restaurants
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LVO Consumer Discretionary
- CHRS Health Care
- Exchange
- LVO Nasdaq
- CHRS Nasdaq
- Market Cap
- LVO 117.0M
- CHRS 134.4M
- IPO Year
- LVO N/A
- CHRS 2014
- Fundamental
- Price
- LVO $0.84
- CHRS $1.07
- Analyst Decision
- LVO Strong Buy
- CHRS Strong Buy
- Analyst Count
- LVO 2
- CHRS 4
- Target Price
- LVO $2.75
- CHRS $5.38
- AVG Volume (30 Days)
- LVO 858.3K
- CHRS 2.0M
- Earning Date
- LVO 02-13-2025
- CHRS 03-12-2025
- Dividend Yield
- LVO N/A
- CHRS N/A
- EPS Growth
- LVO N/A
- CHRS N/A
- EPS
- LVO N/A
- CHRS N/A
- Revenue
- LVO $126,016,000.00
- CHRS $304,340,000.00
- Revenue This Year
- LVO $5.30
- CHRS $2.07
- Revenue Next Year
- LVO N/A
- CHRS N/A
- P/E Ratio
- LVO N/A
- CHRS N/A
- Revenue Growth
- LVO 11.43
- CHRS 44.19
- 52 Week Low
- LVO $0.56
- CHRS $0.66
- 52 Week High
- LVO $2.15
- CHRS $2.65
- Technical
- Relative Strength Index (RSI)
- LVO 34.54
- CHRS 39.03
- Support Level
- LVO $0.82
- CHRS $1.06
- Resistance Level
- LVO $0.95
- CHRS $1.16
- Average True Range (ATR)
- LVO 0.13
- CHRS 0.08
- MACD
- LVO -0.04
- CHRS 0.00
- Stochastic Oscillator
- LVO 3.13
- CHRS 5.56
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.